- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00054535
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have metastatic melanoma.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
- Determine the response rate (partial response or complete remission) in patients with metastatic melanoma treated with vaccinia-tyrosinase vaccine, fowlpox-tyrosinase vaccine, and high-dose interleukin-2.
- Determine the immunologic response, measured by the reactivity of CD4+ and CD8+ T cells and serum immunoglobulins against tyrosinase and melanoma cells, in patients treated with this regimen.
OUTLINE: Patients receive vaccinia-tyrosinase vaccine intramuscularly (IM) on day 1 followed by fowlpox-tyrosinase vaccine IM on days 15 and 29. Patients then receive high-dose interleukin-2 (IL-2) IV over 15 minutes every 8 hours beginning on day 30 for up to 12 doses and again beginning approximately 3 weeks after the initial dose. Patients with stable disease or a minor, mixed, or partial response may receive additional courses of fowlpox-tyrosinase vaccine (2 doses) and IL-2 as above in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 1 additional course beyond achieving CR.
Patients are followed annually for at least 5 years.
PROJECTED ACCRUAL: A total of 19-35 patients will be accrued for this study within 2 years.
Tipo de estudio
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Diagnosis of metastatic melanoma
- Measurable disease
- Disease progression while receiving prior standard treatment
- No ocular or mucosal primary site
- No uncontrolled brain metastases
PATIENT CHARACTERISTICS:
Age
- 16 and over
Performance status
- ECOG 0-1
Life expectancy
- More than 3 months
Hematopoietic
- WBC at least 3,000/mm^3
- Platelet count at least 90,000/mm^3
- No coagulation disorders
Hepatic
- Bilirubin no greater than 1.6 mg/dL (less than 3.0 mg/dL in patients with Gilbert's syndrome)
- AST/ALT less than 3 times normal
- Hepatitis B surface antigen negative
- Hepatitis C antibody negative
Renal
- Creatinine no greater than 1.6 mg/dL
Cardiovascular
- No major cardiovascular illness
Pulmonary
- No major respiratory illness
Immunologic
- HIV negative
- No autoimmune disease
- No active systemic infections
- No primary or secondary immunodeficiency (e.g., hereditary disorders such as ataxia-telangiectasia or Wiskott-Aldrich syndrome or acquired immunodeficiencies after bone marrow transplantation)
- No allergy to eggs
- No prior allergy or untoward reaction to smallpox vaccination (if previously vaccinated)
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
No close contact with the following individuals for 2 weeks after vaccinia vaccination:
- Children under 5 years of age
- Pregnant women
- Individuals with prior or active eczema or other eczematoid skin disorders
- Individuals with other acute, chronic, or exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds)
- Immunosuppressed individuals
- No active atopic dermatitis
- No prior or active eczema
No active cases of the following conditions:
- Extensive psoriasis
- Severe acneiform rash
- Impetigo
- Varicella zoster
- Burns
- Traumatic or pruritic skin conditions
- Open wounds
No unhealed surgical scars
- Healed surgical stomas (e.g., colostomy) allowed
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior recombinant vaccinia or fowlpox vaccines for melanoma
No prior vaccination with full length tyrosinase protein, or a vector encoding the full length protein for melanoma
- Prior individual tyrosinase peptides are allowed
- No prior high-dose interleukin-2
Chemotherapy
- Not specified
Endocrine therapy
- No concurrent oral, IV, topical, or inhaled steroids
Radiotherapy
- Not specified
Surgery
- Recovered from prior surgery
Other
- Recovered from prior therapy for melanoma
- More than 3 weeks since prior systemic therapy for melanoma
- No other concurrent systemic therapy for melanoma
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Enmascaramiento: Ninguno (etiqueta abierta)
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Suzanne L. Topalian, MD, NCI - Surgery Branch
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Melanoma
- Efectos fisiológicos de las drogas
- Agentes antiinfecciosos
- Agentes Antivirales
- Agentes Anti-VIH
- Agentes antirretrovirales
- Agentes antineoplásicos
- Factores inmunológicos
- Aldesleukin
- Vacunas
Otros números de identificación del estudio
- CDR0000270794
- NCI-03-C-0080
- NCI-6119
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre aldesleukina
-
Onur Boyman, MDTerminadoLupus Eritematoso SistémicoSuiza
-
National Institute of Allergy and Infectious Diseases...TerminadoInfecciones por VIHEstados Unidos
-
National Institute of Allergy and Infectious Diseases...Terminado
-
The Methodist Hospital Research InstituteTerminado
-
National Institute of Allergy and Infectious Diseases...Terminado
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...TerminadoInfecciones por VIHEstados Unidos
-
National Institute of Allergy and Infectious Diseases...TerminadoInfecciones por VIHEstados Unidos
-
Chiron CorporationTerminadoInfecciones por VIH | Retinitis por citomegalovirusEstados Unidos
-
National Institute of Allergy and Infectious Diseases...Terminado